Hellemans, R <br/><br/>
Daclizumab Versus Rabbit Antithymocyte Globulin in High-Risk Renal Transplants: Five-Year Follow-up of a Randomized Study.  [electronic resource] 

 -  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons  Jul 2015 
 - 1923-32 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Observational Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1600-6143 
<br/><br/><label>Standard No.: </label>10.1111/ajt.13191  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Animals<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Antilymphocyte Serum--therapeutic use<br/>Daclizumab<br/>Female<br/>Follow-Up Studies<br/>Glomerular Filtration Rate<br/>Graft Rejection--prevention & control<br/>Graft Survival--drug effects<br/>Humans<br/>Immunoglobulin G--therapeutic use<br/>Immunosuppressive Agents--therapeutic use<br/>Kidney Failure, Chronic--surgery<br/>Kidney Function Tests<br/>Kidney Transplantation<br/>Male<br/>Middle Aged<br/>Postoperative Complications<br/>Prognosis<br/>Prospective Studies<br/>Rabbits<br/>Risk Factors